<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02798874</url>
  </required_header>
  <id_info>
    <org_study_id>16qgyyq</org_study_id>
    <nct_id>NCT02798874</nct_id>
  </id_info>
  <brief_title>Effects of Ticagrelor on No-reflow in Patients With Acute ST-segment Elevation Myocardial Infarction</brief_title>
  <official_title>Chinese People's Liberation Army General Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The 'no-reflow' phenomenon after a percutaneous coronary intervention (PCI) in patients with
      acute ST-segment elevation myocardial infarction (STEMI) is a strong predictor of both short-
      and long-term mortality. Faster antiplatelet activity and increased levels of adenosine
      provide a theoretical basis for ticagrelor to effectively prevent no-reflow after PCI. We
      planned to evaluate the effects of ticagrelor on myocardial no-reflow after PCI for STEMI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators enrolled 240 patients with STEMI who were admitted to the Chinese PLA General
      Hospital between September 2013 and March 2015. STEMI was defined as typical chest pain
      lasting N30 min within the previous 12 h, a clear ST-segment elevation of N0.1 mV in ≥2
      contiguous electrocardiographic leads, and elevated blood levels of troponin T. We screen
      high-risk patients through no-reflow risk prediction model， patients were scheduled to
      undergo diagnostic cardiac angiography or percutaneous coronary interventions. We randomly
      assigned eligible patients in a 1:1 ratio to receive either ticagrelor 180 mg or clopidogrel
      600 mg 30 min before PCI.

      The primary efficacy variable was the prevalence of no-reflow assessed immediately post
      procedure. Secondary efficacy variables were troponin T (TnT), high sensitivity C-reactive
      protein (hsCRP), interleukin-6 (IL-6), superoxide dismutase (SOD), malondialdehyde (MDA),
      endothelin-1 (ET-1), and nitric oxide (NO) level
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the prevalence of no-reflow,</measure>
    <time_frame>immediately post procedure</time_frame>
    <description>Anterograde coronary flow in the infarct-related artery was graded according to the thrombolysis in myocardial infarction (TIMI) grading system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>main cardiovascular events</measure>
    <time_frame>90 days</time_frame>
    <description>bleeding, dialysis, myocardial infarction, heart failure and all-cause death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Ticagrelor Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ticagrelor 180 mg 30 min before PCI and 90 mg for 12 months after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel 600 mg 30 min before PCI and 75 mg for 12 months after surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>ticagrelor 180 mg 30 min before PCI and 90 mg for 12 months after surgery</description>
    <arm_group_label>Ticagrelor Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel 600 mg 30 min before PCI and 75 mg for 12 months after surgery</description>
    <arm_group_label>Clopidogrel Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with STEMI who were admitted to the Chinese PLA General Hospital

        Exclusion Criteria:

          -  1.unconscious at presentation; 2.had cardiogenic shock, 3.hypoglycemia, 4.diabetic
             ketoacidosis; 5.had a history of myocardial infarction, stent thrombosis, or renal
             insufficiency; 6.had previously undergone coronary artery bypass surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dai Yun Chen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chinese People's Liberation Army General Hospital</name>
      <address>
        <city>Peking</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Rezkalla SH, Kloner RA. Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory. Catheter Cardiovasc Interv. 2008 Dec 1;72(7):950-7. doi: 10.1002/ccd.21715. Review.</citation>
    <PMID>19021281</PMID>
  </reference>
  <reference>
    <citation>Bolognese L, Carrabba N, Parodi G, Santoro GM, Buonamici P, Cerisano G, Antoniucci D. Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation. 2004 Mar 9;109(9):1121-6. Epub 2004 Feb 16.</citation>
    <PMID>14967718</PMID>
  </reference>
  <reference>
    <citation>Brosh D, Assali AR, Mager A, Porter A, Hasdai D, Teplitsky I, Rechavia E, Fuchs S, Battler A, Kornowski R. Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality. Am J Cardiol. 2007 Feb 15;99(4):442-5. Epub 2006 Dec 20.</citation>
    <PMID>17293180</PMID>
  </reference>
  <reference>
    <citation>Reffelmann T, Kloner RA. The no-reflow phenomenon: A basic mechanism of myocardial ischemia and reperfusion. Basic Res Cardiol. 2006 Sep;101(5):359-72. Review.</citation>
    <PMID>16915531</PMID>
  </reference>
  <reference>
    <citation>Wang JW, Chen YD, Wang CH, Yang XC, Zhu XL, Zhou ZQ. Development and validation of a clinical risk score predicting the no-reflow phenomenon in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Cardiology. 2013;124(3):153-60. doi: 10.1159/000346386. Epub 2013 Mar 8.</citation>
    <PMID>23485798</PMID>
  </reference>
  <reference>
    <citation>Chen Y, Wang C, Yang X, Wang L, Sun Z, Liu H, Chen L. Independent no-reflow predictors in female patients with ST-elevation acute myocardial infarction treated with primary percutaneous coronary intervention. Heart Vessels. 2012 May;27(3):243-9. doi: 10.1007/s00380-011-0144-2. Epub 2011 Apr 28.</citation>
    <PMID>21526420</PMID>
  </reference>
  <reference>
    <citation>Wang J, Chen YD, Zhi G, Xu Y, Chen L, Liu HB, Zhou X, Tian F. Beneficial effect of adenosine on myocardial perfusion in patients treated with primary percutaneous coronary intervention for acute myocardial infarction. Clin Exp Pharmacol Physiol. 2012 Mar;39(3):247-52. doi: 10.1111/j.1440-1681.2012.05668.x.</citation>
    <PMID>22214231</PMID>
  </reference>
  <reference>
    <citation>Teng R, Oliver S, Hayes MA, Butler K. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010 Sep;38(9):1514-21. doi: 10.1124/dmd.110.032250. Epub 2010 Jun 15.</citation>
    <PMID>20551239</PMID>
  </reference>
  <reference>
    <citation>Wittfeldt A, Emanuelsson H, Brandrup-Wognsen G, van Giezen JJ, Jonasson J, Nylander S, Gan LM. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. J Am Coll Cardiol. 2013 Feb 19;61(7):723-7. doi: 10.1016/j.jacc.2012.11.032. Epub 2013 Jan 9.</citation>
    <PMID>23312702</PMID>
  </reference>
  <reference>
    <citation>Steg PG, James S, Harrington RA, Ardissino D, Becker RC, Cannon CP, Emanuelsson H, Finkelstein A, Husted S, Katus H, Kilhamn J, Olofsson S, Storey RF, Weaver WD, Wallentin L; PLATO Study Group. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation. 2010 Nov 23;122(21):2131-41. doi: 10.1161/CIRCULATIONAHA.109.927582. Epub 2010 Nov 8.</citation>
    <PMID>21060072</PMID>
  </reference>
  <reference>
    <citation>Wang CH, Chen YD, Yang XC, Wang LF, Wang HS, Sun ZJ, Liu HB. A no-reflow prediction model in patients with ST-elevation acute myocardial infarction and primary drug-eluting stenting. Scand Cardiovasc J. 2011 Apr;45(2):98-104. doi: 10.3109/14017431.2011.558209. Epub 2011 Feb 17.</citation>
    <PMID>21329416</PMID>
  </reference>
  <reference>
    <citation>Jogiya R, Kozerke S, Morton G, De Silva K, Redwood S, Perera D, Nagel E, Plein S. Validation of dynamic 3-dimensional whole heart magnetic resonance myocardial perfusion imaging against fractional flow reserve for the detection of significant coronary artery disease. J Am Coll Cardiol. 2012 Aug 21;60(8):756-65. doi: 10.1016/j.jacc.2012.02.075. Epub 2012 Jul 18.</citation>
    <PMID>22818072</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2016</study_first_submitted>
  <study_first_submitted_qc>June 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2016</study_first_posted>
  <last_update_submitted>June 13, 2016</last_update_submitted>
  <last_update_submitted_qc>June 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Qian geng</investigator_full_name>
    <investigator_title>associate chief physician</investigator_title>
  </responsible_party>
  <keyword>Ticagrelor</keyword>
  <keyword>No-reflow</keyword>
  <keyword>Acute ST-segment elevation myocardial</keyword>
  <keyword>Reperfusion injury</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

